ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2260

Musculoskeletal Sarcoidosis: A 15-Year Experience from a Tertiary Care Center in the US

Sanjeev Patil1, Masumi Arakane2, Sreedevi Jenigiri3, Elizabeth Field4 and Namrata Singh5, 1Rheumatology, University of Iowa Hospitals and Clinics, Iowa City, IA, 2University of Iowa Hospitals and Clinics, Iowa City, IA, 3Iowa City VA Healthcare System, Iowa City, IA, 4Iowa City VA, Iowa City, IA, 5Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Musculoskeletal and sarcoidosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcoidosis, a systemic disease characterized by non-caseating granulomas within the affected organs. Less than 10% of cases manifest as musculoskeletal (MSK) involvement of joints, muscles and bone tissue. Common first line therapies for MSK sarcoidosis are NSAIDs and systemic steroids. Due to its rarity, studies assessing clinical presentation and therapeutic efficacy of disease modifying drugs are rare.

We aim to determine prevalence of MSK sarcoidosis at University of Iowa Hospitals and clinics, describe epidemiologic and clinical characteristics of MSK sarcoidosis and describe various therapeutic agents and their outcomes in our cohort.

Methods: We conducted an IRB-approved, retrospective electronic medical records (EMR) search using ICD-9 codes for sarcoidosis followed by review of individual records to identify patients with MSK sarcoidosis between January 1, 2000 and December 31, 2014.

MSK sarcoidosis cases were based on:

a. Lofgren syndrome, or

b. biopsy-proven sarcoidosis and chronic arthritis not attributed to other causes, or

c. biopsy-proven sarcoidosis of MSK tissue (bone, muscle).

Clinical data from the MSK sarcoid cases was then entered into a standardized questionnaire created in REDCap. Statistical analysis was done using REDCap.

Results: Among 1016 patients with sarcoidosis, 58 patients met the inclusion criteria, making the prevalence 5.70%. Epidemiological and clinical characteristics were as follows: Mean age (47.21 years); Female (74.14%); Caucasian (82.76%), African American (10.34%), Lofgren syndrome (46.55%), chronic arthritis (24.14%), osseous sarcoid (25.86%), myopathy (6.90%) (Figure 1). Most commonly involved sites in Lofgren syndrome was ankle (96.30%), in chronic arthritis was finger joints (71.43%), in Osseous sarcoid was pelvis (53.33%), in Myopathy was proximal upper and lower extremity muscles.

Treatment was considered not necessary in 14.81% with Lofgren syndrome and 26.67% with osseous sarcoid. Most commonly used medication was prednisone (59.26% Lofgren, 57.14% chronic arthritis, 60% osseous, 75% myopathy). Methotrexate was the most commonly (25.86%) used DMARD. Biologics (anti-TNF agents) were used for chronic arthritis (n=1), osseous sarcoid (n=1) and myopathy (n=1).

Conclusion: To our knowledge, this is the largest case series describing all forms of MSK sarcoidosis in the US since 1984. MSK sarcoidosis appears to be seen in a small fraction of patients with sarcoidosis, with Lofgren syndrome being the most frequent and myopathy least frequent MSK manifestation. Ankle was most commonly involved in Lofgren and finger joints in chronic arthritis. Osseous sarcoid was seen most commonly in pelvis. Prednisone was most commonly used medication and methotrexate was the most commonly used DMARD across all forms of MSK sarcoidosis. Anti-TNF medications were used in a small minority of patients.


Disclosure: S. Patil, None; M. Arakane, None; S. Jenigiri, None; E. Field, None; N. Singh, None.

To cite this abstract in AMA style:

Patil S, Arakane M, Jenigiri S, Field E, Singh N. Musculoskeletal Sarcoidosis: A 15-Year Experience from a Tertiary Care Center in the US [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/musculoskeletal-sarcoidosis-a-15-year-experience-from-a-tertiary-care-center-in-the-us/. Accessed December 8, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/musculoskeletal-sarcoidosis-a-15-year-experience-from-a-tertiary-care-center-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.